SMAIO Stock Earns Key 'Buy' Rating Amid Spine Surgery Tech Boom

DALLAS & LYON – May 05, 2026 – Spine surgery innovator SMAIO (Euronext Growth Paris: ALSMA) received a significant vote of confidence today as Portzamparc, a subsidiary of the BNP Paribas Group, initiated coverage of its stock with a "Buy" recommendation. The move signals growing institutional interest in the French-American company, which is leveraging artificial intelligence and a massive patient database to personalize complex spinal procedures.

In its inaugural report, titled “A Lyon-based tailor offering bespoke solutions for your back,” Portzamparc set a valuation of €8.80 per share for SMAIO. This development not only bolsters the company's credibility within financial markets but also shines a spotlight on its unique position in the highly competitive medical technology landscape. The addition of Portzamparc brings the total number of equity research firms covering SMAIO to three, joining EuroLand Corporate and TP ICAP, both of which also hold positive outlooks on the stock. This growing analyst consensus suggests that SMAIO's strategy of blending software, adaptive implants, and data-driven services is resonating with experts who see potential for substantial growth.

A Surge in Financial Performance and U.S. Growth

The positive analyst coverage is built on a foundation of robust financial performance and strategic market penetration, particularly in the lucrative United States market. SMAIO's full-year 2025 results painted a clear picture of a company in an accelerated growth phase. Consolidated sales surged by an impressive 67% to reach €9.2 million. The primary engine for this growth was the U.S. market, where implant sales skyrocketed by 138% to €7.0 million, accounting for over three-quarters of the company's total revenue.

This top-line growth was accompanied by significant operational improvements. The company's gross margin rate climbed 14 points to a healthy 83%, indicating strong pricing power and manufacturing efficiency. Furthermore, SMAIO demonstrated progress towards profitability, with its EBITDA loss narrowing by 36% to €0.8 million. While the company still posted a net loss, its financial footing has been substantially strengthened. As of December 31, 2025, SMAIO's cash position stood at €5.9 million, bolstered by a €2.5 million fundraising effort and an additional €2.0 million in loans. This was further reinforced in March 2026 by a €3.6 million capital increase subscribed by Eiffel Investment Group, providing the company with the necessary runway to fund its expansion plans.

Investors will be watching closely for the upcoming release of first-quarter 2026 sales on May 12, which will serve as the next key indicator of whether this powerful momentum is being sustained.

Beyond the Stock: Data-Driven Surgery as the Core Innovation

While the financial metrics are compelling, the core of SMAIO's story lies in its technological innovation, which aims to transform the art of spine surgery into a precise science. The company stands apart from competitors through its integrated i-Kontrol platform, a comprehensive ecosystem that supports surgeons before, during, and after a procedure. This platform is built on a "big data" approach, leveraging the company's proprietary KEOPS (KnowledgE base for Orthopaedic PhysicianS) database, which contains meticulously documented data from over 100,000 patient cases.

This vast data repository fuels the i-PLAN software, which uses AI-powered predictive algorithms to help surgeons model a patient's spine, simulate surgical outcomes, and create a precise roadmap for implant placement. The goal is to restore the optimal spinal shape and balance for each individual, moving beyond a one-size-fits-all approach. This pre-operative planning is then seamlessly integrated with the surgical execution phase, i-PERFORM, which utilizes adaptive implants and patient-specific instruments, such as the company's K-Rods, to bring the digital plan to life in the operating room. The cycle is completed by i-CHECK, which facilitates long-term patient monitoring and data collection, continuously enriching the KEOPS database.

This data-driven methodology directly addresses key trends in the global spine market, a sector valued at over $21 billion and driven by an aging population and rising prevalence of spinal disorders. As the industry moves towards minimally invasive techniques, robotics, and personalization, SMAIO's established expertise in leveraging clinical data gives it a significant competitive edge.

Strategic Alliances Pave the Way in a Crowded Market

Penetrating the North American market, which is dominated by giants like Medtronic and DePuy Synthes, is a formidable challenge for any emerging company. SMAIO's strategy has been to forge key alliances through its KEOPS-4ME open platform, designed specifically to allow U.S. surgical companies and their surgeons to integrate SMAIO's planning technology with their preferred implant systems.

This collaborative approach has led to two landmark distribution agreements signed in late 2025. A partnership with Highridge Medical, one of the world's largest privately held spine companies, grants its extensive network of surgeons access to SMAIO's powerful spinal realignment planning tools. Shortly after, SMAIO announced a similar agreement with Orthofix, another global medical technology leader. These partnerships are not just distribution channels; they are powerful endorsements of SMAIO's technology, allowing the company to scale its U.S. presence rapidly without the massive capital outlay required to build a direct sales force from scratch.

By focusing on education and adoption, including hosting "Think Tank" events for leading spine surgeons, SMAIO is building a community of advocates for its technology. These strategic collaborations, combined with a focus on surgeon training, are expected to be major growth catalysts beginning in the second half of 2026, positioning SMAIO as a key enabler of next-generation spine surgery in the world's largest healthcare market.